Posted by Michael Wonder on 03 Aug 2021
Moderna receives FDA fast track designation for respiratory syncytial virus vaccine (mRNA-1345)
3 August 2021 - Moderna today announced that the U.S. FDA has granted fast track designation for mRNA-1345, its investigational single dose mRNA vaccine against respiratory syncytial virus in adults older than 60 years of age.
The Company previously received fast track designation for its COVID-19 vaccine candidate, Zika vaccine candidate (mRNA-1893), methylmalonic acidaemia (mRNA-3704) and propionic acidaemia (mRNA-3927) programs.
